- World first: human liver kept alive and functioning on machine outside patient’s body
- World first: livers kept alive on device successfully transplanted into two patients
- Oxford University machine could as much as double number of livers for transplant
- Technology currently being trialled for first time with humans at King’s College Hospital in London
In a world first, a donated human liver has been ‘kept alive’ outside a human being and then successfully transplanted into a patient in need of a new liver.
So far the procedure has been performed on two patients on the liver transplant waiting list and both are making excellent recoveries.
Currently transplantation depends on preserving donor organs by putting them ‘on ice’ – cooling them to slow their metabolism. But this often leads to organs becoming damaged.
The technology, developed at Oxford University and now being trialled at the liver transplant centre at King’s College Hospital as part of a controlled clinical investigation, could preserve a functioning liver outside the body for 24 hours. A donated human liver connected to the device is raised to body temperature and oxygenated red blood cells are circulated through its capillaries. Once on the machine, a liver functions normally just as it would inside a human body, regaining its colour and producing bile.
The results from the first two transplants, carried out at King’s College Hospital in February 2013, suggest that the device could be useful for all patients needing liver transplants. Based on pre-clinical data, the new device could also enable the preservation of livers which would otherwise be discarded as unfit for transplantation – potentially as much as doubling the number of organs available for transplant and prolonging the maximum period of organ preservation to 24 hours.
‘These first clinical cases confirm that we can support human livers outside the body, keep them alive and functioning on our machine and then, hours later, successfully transplant them into a patient,’ said Professor Constantin Coussios of Oxford University’s Department of Engineering Science, one of the machine’s inventors and Technical Director of OrganOx, the University spin-out created to bring the device from bench to bedside.
‘The device is the very first completely automated liver perfusion device of its kind: the organ is perfused with oxygenated red blood cells at normal body temperature, just as it would be inside the body, and can for example be observed making bile, which makes it an extraordinary feat of engineering.
‘It was astounding to see an initially cold grey liver flushing with colour once hooked up to our machine and performing as it would within the body. What was even more amazing was to see the same liver transplanted into a patient who is now walking around.’
‘Whilst for these two transplants we only needed to keep the livers alive for up to 10 hours, in other experiments we have shown we can preserve a functioning liver and monitor its function outside the body for periods up to 24 hours.’
Professor Nigel Heaton, Consultant Liver Transplant Surgeon and Director of Transplant Surgery at King’s College Hospital, said: ‘Despite all the advances in modern medicine, the fundamentals of liver transplantation have not changed in decades. This is why the device is so exciting. If we can introduce technology like this into everyday practice, it could be a real, bona fide game changer for transplantation as we know it. Buying the surgeon extra time extends the options open to our patients, many of whom would otherwise die waiting for an organ to become available.’
Mr Wayel Jassem, Consultant Liver Transplant Surgeon at King’s College Hospital, who performed both transplant operations, said: ‘There is always huge pressure to get a donated liver to the right person within a very short space of time. For the first time, we now have a device that is designed specifically to give us extra time to test the liver, to help maximise the chances of the recipient having a successful outcome. This technology has the potential to be hugely significant, and could make more livers available for transplant, and in turn save lives.’
Ian Christie, 62, the first person to receive a transplanted liver kept alive on the device, said: ‘In May 2012, I was told I had cirrhosis of the liver and without a transplant I had an estimated 12-18 months to live. I was placed on the waiting list but I was told there was about 12-18 months to wait for a liver of my type. I was very worried it was cutting it a bit too fine and I wouldn’t get a transplant.
‘The waiting is horrible. Sometimes I would forget about the transplant but then I would catch sight of the bag in the corner of the room that I had packed ready to go and then I would remember. You’re waiting for the phone to ring, wondering “Are they ever going to call me? Are they ever going to call me?”.
‘I took part in the trial because I just think it’s the right thing to do. If the device can help more people in my situation in the future, it’s my duty to help. I trusted that the doctors wouldn’t go ahead with it unless they were absolutely sure so I knew there wasn’t a risk to my transplant.
‘Three days after the surgery, Mr Jassam from King’s and the professors from Oxford arrived in my room with absolutely beaming smiles. They look like they are normally quite serious gentlemen so I knew it was a good sign to see them so pleased.
‘I feel better than I’ve felt for 10-15 years, even allowing for the pain and wound that’s got to heal. I’m getting better and better day by day. I just feel so alive!
‘It’s so easy to get carried away and become euphoric, but things can still go wrong, so I’m trying to keep my feet on the ground and take it day by day.’
Professor Coussios and Professor Peter Friend, of Oxford University’s Nuffield Department of Surgical Sciences and Director of the Oxford Transplant Centre, and colleagues have been researching the technology since 1994.
Professor Peter Friend said: ‘Transplant surgery is a victim of its own success with far more people needing transplants than there are donor organs available. This device has the potential to change that situation radically. By enabling us to transplant many organs that are unusable with current techniques, this technology could bring benefit to a large number of patients awaiting transplants, many of whom currently die whilst still waiting.
‘At present, organ transplantation depends upon cooling the organ to ice temperature to slow down its metabolism, but this does not stop it deteriorating and, if the organ is already damaged in some way, perhaps by being deprived of oxygen, then the combined effect can be disastrous. Many potential donor organs are declined as being unsuitable for this reason.
‘This new technique allows us to assess how well an organ is working before having to decide whether to commit a patient to the operation. So this technology promises to quality-assure organs which would otherwise be discarded. This would increase the number of transplants without increasing the risks. It will make a real difference to what happens to patients on the waiting list without requiring any change in current donation practices.’
In 2008 the spin-out company OrganOx was formed, through the University’s technology transfer firm Isis Innovation, in order to commercialise the Oxford research. OrganOx, headed by CEO Dr Les Russell, developed the device for these first clinical trials.
‘In Europe and the US, around 13,000 liver transplants are undertaken each year,’ said OrganOx CEO Dr Les Russell. ‘However, there is a combined waiting list of around 30,000 patients and up to 25 per cent of these patients die whilst awaiting transplantation. Meanwhile, over 2000 livers are discarded annually because they are either damaged by oxygen deprivation or do not survive cold preservation due to elevated intracellular fat’.